Immatics N.V. (IMTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Immatics N.V. (IMTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.99

-0.26 (-4.16%)

At close: Jan 14, 2025, 3:59 PM

5.97

-0.33%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	5.88
Market Cap	714.94M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.63
PE Ratio (ttm)	-9.51
Forward PE	n/a
Analyst	Buy

Ask	9.55
Volume	519,732
Avg. Volume (20D)	674,678
Open	6.25
Previous Close	6.25
Day's Range	5.96 - 6.40
52-Week Range	5.96 - 13.77
Beta	undefined

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 12, 2018

Employees 542

Stock Exchange NASDAQ

Ticker Symbol IMTX

Website https://www.immatics.com

Analyst Forecast

According to 4 analyst ratings, the average rating for IMTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 167.11% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Immatics N.V. is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of $16.16M, reflecting a -5.7% YoY shrinking and earnings per share of -0.31, making a -3.13% decrease YoY.

Why Price Moved

3 months ago · Source

-15.54%

Immatics shares are trading lower after the compan... Unlock content with Pro Subscription

10 months ago · Source

-5.89%

Immatics shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.

News

6 days ago · zacks.com

New Strong Buy Stocks for January 9th

AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.

1 week ago · zacks.com

Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

What Makes Immatics (IMTX) a New Buy Stock

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates

Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.

2 months ago · zacks.com

Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.